Receiving an injection of GVAX, a vaccine which was developed by combining autologous tumor cells with an allogeneic cell line that secretes GM-CSF, resulted in enhanced survival rates for patients with metastatic NSCLC who had previously experienced chemotherapy failure. This evidence concerns the gene CSF2 and non-small cell lung carcinoma.